Related Experiment Videos
Apathy: a treatable syndrome
R S Marin1, B S Fogel, J Hawkins
1Western Psychiatric Institute and Clinic, University of Pittsburgh, PA 15213, USA.
The Journal of Neuropsychiatry and Clinical Neurosciences
|January 1, 1995
Summary
Apathy, a common symptom in neuropsychiatric disorders, can be effectively treated with various medications. This study highlights pharmacological interventions for apathy, offering hope for previously untreatable patients.
Area of Science:
- Neuropsychiatry
- Behavioral Neurology
- Pharmacology
Background:
- Apathy is a prevalent symptom in various neuropsychiatric disorders, often presenting as a distinct syndrome.
- Understanding the pathophysiology of apathy is crucial for developing effective treatment strategies.
- Current treatment options for apathy are limited, leaving many patients with unmet needs.
Observation:
- This study reviewed patient histories demonstrating significant and sustained improvement in apathy following pharmacological treatment.
- The observed benefits were associated with diverse etiologies, including dementia, stroke, traumatic brain injury, and alcoholism.
- A range of pharmacological agents, such as amantadine, amphetamines, bupropion, and methylphenidate, were utilized.
Findings:
- Apathy can be considered a distinct behavioral dimension with its own underlying pathophysiology.
- Pharmacological interventions show promise in treating apathy across a spectrum of neuropsychiatric conditions.
- Successful treatment of apathy was observed in patients with varied neurological and psychiatric histories.
Implications:
- These findings suggest that apathy may be a treatable condition in many patients previously considered untreatable.
- Studying apathy treatment can advance the clinical care and scientific understanding of neuropsychiatric disorders.
- This research opens new avenues for managing apathy and improving patient outcomes across the lifespan.